Thermo Fisher Scientific Opens Biologics Manufacturing Site in Lengnau, Switzerland
As part of its strategic partnership with CSL Limited, Thermo Fisher announced that it has assumed operational responsibility for a new 1.5-million-square-foot biologics manufacturing site in Lengnau, Switzerland. The site will become part of Thermo Fisher’s global biologics manufacturing network and will leverage highly flexible bioproduction technologies, including both single-use and stainless steel with up to 12,500L bioreactor capacity.
Learn More »
IndustryWeek Best Plants Award Winner 2021
Our Greenville, NC manufacturing site is a recipient of a 2021 IndustryWeek Best Plants Award, which recognizes North American manufacturing facilities for excellence across a range of factors, including productivity, customer care and employee engagement. This is the fourth IndustryWeek Best Plants Award for the company, which previously received the award for its sites in Auburn, Ala.; Asheville, N.C.; and Marietta, Ohio.
Learn More »
Accelerate development of plasmid-based medicines and vaccines
Responding to critical market capacity constraints, Thermo Fisher announces the official opening of new 67,000 sqft cGMP plasmid DNA manufacturing facility in Carlsbad, CA. This site expands clinical and commercial capabilities for cGMP plasmid DNA used as a critical raw material to develop and manufacture cell and gene-based therapies in addition to capabilities to produce large-scale plasmid DNA as a primary drug substance for DNA therapies.
Learn More »
Thermo Fisher Introduces New Quick to Clinic™ Solution at BIO Digital 2021
New and emerging biopharma companies working on early development can now leverage a better lab-to-clinic drug development solution designed to accelerate the journey from DNA to drug product. Thermo Fisher’s enhanced Quick to Clinic solution may help biopharma companies reach Phase I/First-In-Human trials and file for Investigational New Drug (IND) review in as little as 13 months from transfection.
Learn More »
